These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Biochemical modulation of the catabolism and tissue uptake of the anticancer drug 5-fluorouracil by 5-bromovinyluracil: assessment with metabolic (19)F MR imaging. Brix G; Bellemann ME; Haberkorn U Magn Reson Med; 1999 Nov; 42(5):936-43. PubMed ID: 10542353 [TBL] [Abstract][Full Text] [Related]
3. Direct detection of intratumoral 5-fluorouracil trapping using metabolic 19F MR imaging. Brix G; Bellemann ME; Gerlach L; Haberkorn U Magn Reson Imaging; 1999 Jan; 17(1):151-5. PubMed ID: 9888408 [TBL] [Abstract][Full Text] [Related]
4. Mapping the biodistribution and catabolism of 5-fluorouracil in tumor-bearing rats by chemical-shift selective 19F MR imaging. Brix G; Bellemann ME; Haberkorn U; Gerlach L; Bachert P; Lorenz WJ Magn Reson Med; 1995 Sep; 34(3):302-7. PubMed ID: 7500866 [TBL] [Abstract][Full Text] [Related]
5. Contrast-enhanced MR imaging of postoperative scars and VX2 carcinoma in rabbits: comparison of macromolecular contrast agent and gadopentetate dimeglumine. Lee JW; Moon WK; Weinmann HJ; Kim SJ; Kim JH; Park SH; Kim TJ; Yoon CJ; Kim YH; Cho EY; Ha SW; Kang WS; Chang KH Radiology; 2003 Oct; 229(1):132-9. PubMed ID: 14519873 [TBL] [Abstract][Full Text] [Related]
6. Real-time follow-up of 5-fluorouracil metabolism in the liver of tumor patients by means of F-19 MR spectroscopy. Semmler W; Bachert-Baumann P; Gückel F; Ermark F; Schlag P; Lorenz WJ; van Kaick G Radiology; 1990 Jan; 174(1):141-5. PubMed ID: 2104675 [TBL] [Abstract][Full Text] [Related]
7. Assessment of the biodistribution and metabolism of 5-fluorouracil as monitored by 18F PET and 19F MRI: a comparative animal study. Brix G; Bellemann ME; Haberkorn U; Gerlach L; Lorenz WJ Nucl Med Biol; 1996 Oct; 23(7):897-906. PubMed ID: 8971857 [TBL] [Abstract][Full Text] [Related]
9. [In-vivo 19F-MRS study of 5-fluorouracil (5-FU) metabolism on tumors]. Harada M; Nishitani H; Shirahama T; Koga K; Miura I Gan To Kagaku Ryoho; 1991 Jan; 18(1):75-80. PubMed ID: 1899014 [TBL] [Abstract][Full Text] [Related]
10. Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging. Sun HY; Lee JM; Shin CI; Lee DH; Moon SK; Kim KW; Han JK; Choi BI Invest Radiol; 2010 Feb; 45(2):96-103. PubMed ID: 20057319 [TBL] [Abstract][Full Text] [Related]
11. Enhancement of liver parenchyma after injection of hepatocyte-specific MRI contrast media: a comparison of gadoxetic acid and gadobenate dimeglumine. Filippone A; Blakeborough A; Breuer J; Grazioli L; Gschwend S; Hammerstingl R; Heinz-Peer G; Kittner T; Laghi A; Leen E; Lencioni R; Lucidarme O; Remplik P; Robinson PJ; Ruehm SG; Schaefer F; Stoupis C; Tombach B; Valette PJ; Zech CJ; Huppertz A J Magn Reson Imaging; 2010 Feb; 31(2):356-64. PubMed ID: 20099349 [TBL] [Abstract][Full Text] [Related]
12. Gadobutrol for magnetic resonance imaging of chronic myocardial infarction: intraindividual comparison with gadopentetate dimeglumine. Durmus T; Schilling R; Doeblin P; Huppertz A; Hamm B; Taupitz M; Wagner M Invest Radiol; 2012 Mar; 47(3):183-8. PubMed ID: 22183078 [TBL] [Abstract][Full Text] [Related]
13. Prediction of chemotherapeutic response of colorectal liver metastases with dynamic gadolinium-DTPA-enhanced MRI and localized 19F MRS pharmacokinetic studies of 5-fluorouracil. van Laarhoven HW; Klomp DW; Rijpkema M; Kamm YL; Wagener DJ; Barentsz JO; Punt CJ; Heerschap A NMR Biomed; 2007 Apr; 20(2):128-40. PubMed ID: 17006886 [TBL] [Abstract][Full Text] [Related]
14. Differentiation of hepatic hyperintense lesions seen on gadoxetic acid-enhanced hepatobiliary phase MRI. Suh YJ; Kim MJ; Choi JY; Park YN; Park MS; Kim KW AJR Am J Roentgenol; 2011 Jul; 197(1):W44-52. PubMed ID: 21700994 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of renal function in normal and hydronephrotic kidneys in rats using gadolinium diethylenetetramine-pentaacetic acid enhanced dynamic magnetic resonance imaging. Wen JG; Chen Y; Ringgaard S; Frøkiaer J; Jørgensen TM; Stødkilde-Jørgensen H; Djurhuus JC J Urol; 2000 Apr; 163(4):1264-70. PubMed ID: 10737526 [TBL] [Abstract][Full Text] [Related]
16. Fluoropyrimidine chemotherapy in a rat model: comparison of fluorouracil metabolite profiles determined by high-field 19F-NMR spectroscopy of tissues ex vivo with therapy response and toxicity for locoregional vs systemic infusion protocols. Lutz NW; Naser-Hijazi B; Koroma S; Berger MR; Hull WE NMR Biomed; 2004 May; 17(3):101-31. PubMed ID: 15137037 [TBL] [Abstract][Full Text] [Related]
17. Optimization of localized 19F magnetic resonance spectroscopy for the detection of fluorinated drugs in the human liver. Klomp DW; Van Laarhoven HW; Kentgens AP; Heerschap A Magn Reson Med; 2003 Aug; 50(2):303-8. PubMed ID: 12876706 [TBL] [Abstract][Full Text] [Related]
18. Investigations in vivo of the effects of carbogen breathing on 5-fluorouracil pharmacokinetics and physiology of solid rodent tumours. McSheehy PM; Port RE; Rodrigues LM; Robinson SP; Stubbs M; van der Borns K; Peters GJ; Judson IR; Leach MO; Griffiths JR Cancer Chemother Pharmacol; 2005 Feb; 55(2):117-28. PubMed ID: 15592719 [TBL] [Abstract][Full Text] [Related]
19. Combined quantification of liver perfusion and function with dynamic gadoxetic acid-enhanced MR imaging. Sourbron S; Sommer WH; Reiser MF; Zech CJ Radiology; 2012 Jun; 263(3):874-83. PubMed ID: 22623698 [TBL] [Abstract][Full Text] [Related]
20. Gadoxetic acid-enhanced hepatobiliary phase MRI and high-b-value diffusion-weighted imaging to distinguish well-differentiated hepatocellular carcinomas from benign nodules in patients with chronic liver disease. Lee MH; Kim SH; Park MJ; Park CK; Rhim H AJR Am J Roentgenol; 2011 Nov; 197(5):W868-75. PubMed ID: 22021534 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]